Prognostic value of ctDNA-derived maximum somatic allele frequency in patients with metastatic gastric cancer.

ABSTRACT:

Background

Metastatic gastric cancer (GC) is biologically heterogeneous; however, current staging classifies all metastatic cases as stage IV without reflecting this variability. Circulating tumor DNA (ctDNA)-derived biomarkers, including maximum somatic allele frequency (MSAF), may serve as surrogates for tumor burden and underlying tumor biology.

Objectives

This study aimed to evaluate the prognostic significance of baseline MSAF in patients with metastatic GC receiving first-line palliative chemo or chemoimmunotherapy.

Design

This was a retrospective, single-center cohort study of consecutively tested patients.

Methods

We analyzed 108 patients with pathologically confirmed metastatic gastric adenocarcinoma who underwent baseline ctDNA next-generation sequenc

SUBMITTER: Kim C 

PROVIDER: S-EPMC12847658 | biostudies-literature | 2026

REPOSITORIES: biostudies-literature